{"nctId":"NCT01492426","briefTitle":"Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection","startDateStruct":{"date":"2012-01"},"conditions":["Hepatitis C"],"count":605,"armGroups":[{"label":"Daclatasvir + Peginterferon alfa-2a + Ribavirin","type":"EXPERIMENTAL","interventionNames":["Drug: Daclatasvir","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]},{"label":"Telaprevir + Peginterferon alfa-2a + Ribavirin","type":"EXPERIMENTAL","interventionNames":["Drug: Telaprevir","Drug: Peginterferon alfa-2a","Drug: Ribavirin"]}],"interventions":[{"name":"Daclatasvir","otherNames":["BMS-790052"]},{"name":"Telaprevir","otherNames":["Incivek®"]},{"name":"Peginterferon alfa-2a","otherNames":["Pegasys®"]},{"name":"Ribavirin","otherNames":["Copegus®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Participants chronically infected with hepatitis C virus (HCV) genotype 1a or 1b\n* HCV RNA viral load ≥10,000 IU/mL\n* No prior treatment including but not limited to interferon, ribavirin, and direct-acting antivirals\n* No history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1 year\n* Body mass index of 18 to 35 kg/m\\^2\n* Negative for HIV and hepatitis B virus\n\nKey Exclusion Criteria:\n\n* Evidence of decompensated liver disease\n* Evidence of medical condition other than HCV contributing to chronic liver disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","description":"SVR12 was defined as hepatitis C virus RNA levels to be lower than the limit of quantitation, ie, 25 IU/mL target detected or target not detected at follow-up Week 12.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.1","spread":null},{"groupId":"OG001","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Genotype 1b Participants With Rapid Virologic Response (RVR) at Week 4","description":"RVR was defined as hepatitis c virus RNA levels lower than lower limit of quantitation, ie, 25 IU/mL target not detected at Week 4 of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Genotype 1b Participants With Extended Rapid Virologic Response (eRVR) at Both Week 4 and Week 12","description":"eRVR was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target not detected at both Weeks 4 and 12 of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"73.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Genotype 1b Participants With Complete Early Virologic Response (cEVR)","description":"cEVR was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target not detected at Week 12 of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"90.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 24 (SVR24)","description":"SVR24 was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target detected or target not detected at follow-up week 24 of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":null},{"groupId":"OG001","value":"80.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Genotype 1a Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","description":"SVR12 was defined as hepatitis C virus RNA levels lower than the lower limit of quantitation, ie, 25 IU/mL target detected or target not detected at follow-up week 12 of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.9","spread":null},{"groupId":"OG001","value":"69.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":402},"commonTop":["Fatigue","Anaemia","Headache","Pruritus","Rash"]}}}